Baricitinib delays the progression of type 1 diabetes
In a world-first, ATIC researchers lead by Professor’s Thomas Kay and Helen Thomas have shown that baricitinib, an immunotherapy treatment commonly used in rheumatoid arthritis, can delay the progression of type 1 diabetes and preserve the body’s ability to make its own insulin.
What does ATIC do?
ATIC is working across six distinct interconnected Domains to ensure maximum impact and fulfil our bold vision.
Clinical trials
Drive the implementation of immunotherapy clinical trials throughout Australia and New Zealand
Community engagement
Work closely with the type 1 diabetes community across the research cycle, from trial development through recruitment to communication of...
Data management
Harmonise data collection and ensure linkage with national and international diabetes networks.
Education and training
Train, equip and update clinicians, scientists and the wider community on the fundamentals of immunotherapy, as well as the latest...
Preclinical and translation
Attract immunotherapy trials to Australasia through innovation: the discovery of improved biomarkers, development of new therapies, and facilitation of biosample...
Regulation and government
Advocate for regulatory approval and government funding of immunotherapy treatments for type 1 diabetes.
T1D RELAY - Rituximab-pvvr and Abatacept Newly Diagnosed Study
ATIC is conducting the TrialNet lead T1D RELAY trial in Melbourne at The Royal Melbourne Hospital. T1D RELAY is available for people ages 8-45 years who have been diagnosed with type 1 diabetes in the last three months.
PANDA (Pan autoantibody negative diabetes in adults) study
April 2024
Seminar 15, Beyond Insulin Seminar Series – Dr Shivani Patel from the Garvan Institute of Medical Research will present ‘PANDA (Pan autoantibody negative diabetes in adults) study’.
Lessons from a failed coeliac disease trial: a new way forwards?
March 2024
Seminar 14, Beyond Insulin Seminar Series – Associate Professor Jason Tye-Din from WEHI will present ‘Lessons from a failed coeliac disease trial: a new way forwards?’
Using Type 1 Diabetes Genetic Risk Scores for Prediction and Diagnosis of Type 1 Diabetes
February 2024
Seminar 13, Beyond Insulin Seminar Series – Dr Maria Redondo from Baylor College of Medicine, Houston, Texas provides an update on T1D Genetic Risk Scores in T1D
Research breakthrough
December 2023
In a world-first, ATIC researchers lead by Professor’s Thomas Kay and Helen Thomas have shown that baricitinib, an immunotherapy treatment commonly used in rheumatoid arthritis, can delay the progression of type 1 diabetes…
We partner with global leaders in our field
Supported by
Coordinating Centre
